Pinctada fucata active polypeptide PFAP-1 as well as preparation method and application thereof

By extracting and recombinantly expressing the active polypeptide PFAP-1 from Hepu Pearl, the problems of high antibacterial drug resistance and hemolytic activity are solved, and effective inhibition and antioxidant effects on methicillin-resistant Staphylococcus aureus are achieved. It has a wide range of drug and food application prospects.

CN118910069APending Publication Date: 2024-11-08GUANGXI UNIV OF CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410888451.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-04
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing antibacterial drugs Due to the excessive use of antibiotics, it is difficult for the existing technology to effectively overcome the drug resistance problem. Some antibacterial peptides have high hemolytic activity, antioxidant and inhibit the activity of angiotensin-converting enzyme 2 in their application. A problem of insufficient.

Method used

The active polypeptide PFAP-1 was extracted from Hepu Pearl and recombinantly expressed, which encodes DNA molecules to the expression vector, transfects prokaryotic cells to express the polypeptide, optimizes and purifies chemically to prepare anti-Stabas aureus, Antioxidant and inhibiting the activity of angiotensin-converting enzyme 2.

Benefits of technology

PFAP-1 can significantly inhibit the growth of methicillin-resistant Staphylococcus aureus in vitro, has low hemolytic activity, has strong antioxidant activity and inhibit the activity of angiotensin-converting enzyme 2, providing new antibacterial drugs and drug-causing Dual-purpose polypeptide products.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910069A_ABST
    Figure CN118910069A_ABST
Patent Text Reader

Abstract

The invention discloses a pinctada fucata active polypeptide PFAP-1 as well as a preparation method and application thereof, and belongs to the technical field of biomedicine. The method comprises the following steps: obtaining a gene sequence of a protein with an unknown function from pinctada fucata, optimizing a codon, synthesizing by using a chemical method, constructing to a prokaryotic expression vector pET-30a, performing induced expression to obtain an inclusion body protein, and performing denaturation and renaturation to obtain a target polypeptide PFAP-1. According to the present invention, the Pinctada fucata recombinant polypeptide PFAP-1 can inhibit the growth of MRSA in vitro, can dissolve MRSA to death, and has low hemolytic activity, such that the Pinctada fucata recombinant polypeptide PFAP-1 can be used for preparing anti-staphylococcus aureus drugs, and provides a novel raw material for prevention and treatment of staphylococcus aureus infectious diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical technology, and in particular to an active polypeptide PFAP-1 of Pinctada fucata and a preparation method and application thereof. Background Art

[0002] Pinctada martensii, also known as Pinctada fucata, belongs to the phylum Mollusca, class Lamelli-branchia, order Pterioida, family Pteriidae, genus Pinctada. It is the main shellfish producing seawater pearls (also known as Hepu pearls) in southern my country. Except for a small amount of fresh food, most of the meat of Pinctada martensii is sold cheaply as animal feed after pearls are taken out, which is not fully utilized. The meat of Hepu pearl oyster is rich in nutrients and various active ingredients, and has both medicinal and edible value. It is of great significance to develop bioactive peptides from it, which can promote the increase of protein added value of Hepu pearl oyster meat and the development of new polypeptide foods and drugs.

[0003] Due to the overuse of antibiotics, many pathogens have developed multi-drug resistance. At present, antimicrobial resistance seriously threatens human health, so it is of great significance to develop new antibacterial drugs that can overcome resistance. Among them, antimicrobial peptides are not easy to develop widespread drug resistance because they preferentially attack bacterial cell membranes, and have become a key area for the current research and development of new antimicrobial drugs. In addition, many studies have also found that some antimicrobial peptides not only have strong antibacterial activity, but also have antioxidant, anti-tumor, immunomodulatory and other activities. Therefore, in this patent, some biological activities of the recombinantly expressed Hepu Pearl Oyster active peptide PFAP-1 are explored to provide experimental data for its further development. Summary of the invention

[0004] The purpose of the present invention is to provide a Pinctada fucata active polypeptide PFAP-1 and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art.

[0005] To achieve the above object, the present invention provides the following solutions:

[0006] One of the technical solutions of the present invention is a DNA molecule encoding the active peptide PFAP-1 from the Pinctada fucata, and its nucleotide sequence is shown in SEQ ID NO.3.

[0007] The second technical solution of the present invention is an expression vector, comprising the DNA molecule.

[0008] The third technical solution of the present invention is an engineered bacterium, comprising the expression vector.

[0009] The fourth technical solution of the present invention is a method for preparing the active polypeptide PFAP-1 of the Pearl oyster, which comprises using the expression vector to transfect prokaryotic cells to express the active polypeptide PFAP-1 of the Pearl oyster; or using the engineered bacteria to express the active polypeptide PFAP-1 of the Pearl oyster.

[0010] The fifth technical solution of the present invention is the use of the active polypeptide PFAP-1 of the Pearl oyster in the preparation of a product for inhibiting methicillin-resistant Staphylococcus aureus. The amino acid sequence of the active polypeptide PFAP-1 of the Pearl oyster is shown in SEQ ID NO.1.

[0011] The sixth technical solution of the present invention is the use of the active polypeptide PFAP-1 of the Pearl oyster in the preparation of antioxidant products, and the amino acid sequence of the active polypeptide PFAP-1 of the Pearl oyster is shown in SEQ ID NO.1.

[0012] The seventh technical solution of the present invention is the use of the active polypeptide PFAP-1 of the Pearl oyster in the preparation of a drug for inhibiting the activity of angiotensin converting enzyme 2, wherein the amino acid sequence of the active polypeptide PFAP-1 of the Pearl oyster is shown in SEQ ID NO.1.

[0013] Based on the above technical solution, the present invention has the following technical effects:

[0014] The invention obtains a gene sequence of a protein of unknown function from the pearl oyster, synthesizes it by chemical method after codon optimization, constructs it into a prokaryotic expression vector pET-30a, induces expression, obtains inclusion body protein, and obtains the target polypeptide PFAP-1 through denaturation and renaturation. It can inhibit the growth of MRSA in vitro, and can dissolve MRSA to kill it, and its hemolytic activity is low. Therefore, the recombinant polypeptide PFAP-1 of the pearl oyster of the invention can be used to prepare anti-Staphylococcus aureus drugs, and provides a new raw material for preventing and treating Staphylococcus aureus infectious diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0016] Figure 1Optimization and synthesis of the PFAP-1 sequence of the Hepu pearl oyster gene, construction of recombinant plasmid and identification. (A) The original sequence, optimized sequence and corresponding amino acid sequence of the Hepu pearl oyster gene PFAP-1. (B) Codon usage of the wild-type gene PFAP-1 of the Hepu pearl oyster. (C) Codon usage of the optimized PFAP-1 gene. (D) Schematic diagram of the recombinant plasmid. (E) Double enzyme digestion verification results of the recombinant plasmid; M is DNA marker, 1 is the product of double enzyme digestion of the recombinant plasmid, and 2 is the recombinant plasmid.

[0017] Figure 2 Bioinformatics analysis of the active peptide PFAP-1 from the pearl oyster. (A) Prediction of the transmembrane domain of the active peptide PFAP-1 from the pearl oyster. (B) Prediction of the secondary structure of the active peptide PFAP-1 from the pearl oyster. (C) Prediction of the tertiary structure of the active peptide PFAP-1 from the pearl oyster.

[0018] Figure 3 The expression, purification and Western blot identification of PFAP-1 from Pinctada fucata by E. coli. (A) SDS-PAGE analysis of PFAP-1 polypeptide expression in BL21 (DE3); Lane M: SDS-PAGE Protein Marker; Lane 1: 15℃ induction for 16h; Lane 2: 37℃ induction for 16h; Lane 3: supernatant after whole bacteria rupture; Lane 4: precipitate after whole bacteria rupture. (B) SDS-PAGE analysis of supernatant soluble PFAP-1 recombinant polypeptide purification results; Lane M: SDS-PAGE Protein Marker; Lane 1: supernatant after whole bacteria rupture and centrifugation; Lane 2: effluent after supernatant incubated with Ni-IDA; Lane 3-4: 50mM Imidazole elution fraction; Lane 5-6: 100mM Imidazole elution fraction; Lane 7-11: 500mMImidazole elution fraction. (C) Purification results of recombinant PFAP-1 peptide from inclusion bodies; Lane M: SDS-PAGE Protein Marker; Lane 1: supernatant after centrifugation of inclusion bodies; Lane 2: effluent after incubation of supernatant with Ni-IDA; Lane 3: 50mM Imidazole elution fraction; Lane 4-7: 500mM Imidazole elution fraction. (D) Quality inspection results of purified recombinant PFAP-1 peptide; Lane 1: BSA (1.00μg); Lane 2: PFAP-1 peptide (0.60μg). (E) WB verification of recombinant PFAP-1 peptide; Lane 2: PFAP-1 peptide (0.60μg).

[0019] Figure 4 The molecular weight determination and mass spectrometry identification of PFAP-1 recombinant polypeptide. (A) The molecular weight determination diagram of PFAP-1 recombinant polypeptide. (B) The fingerprint of PFAP-1 recombinant polypeptide peptide segment CDCPRLLDSLRSNCK.

[0020] Figure 5 The antibacterial activity of PFAP-1 recombinant protein against MRSA. (A) The inhibition zone of PFAP-1 recombinant protein against MRSA. (B) The statistical results of the diameter of the inhibition zone of PFAP-1 against MRSA.

[0021] Figure 6 The MIC and MBC determination of PFAP-1 recombinant peptide against MRSA and the plotting of growth curve. (A) TTC color development. (B) OD 485 Absorbance numerical statistics. (C) Growth of plate colonies. (D) Effect of PFAP-1 recombinant peptide on MRSA growth curve.

[0022] Figure 7 The scanning electron microscope observation shows the effect of PFAP-1 recombinant polypeptide on the microscopic morphology of MRSA. (A) Scanning electron microscope observation shows the effect of PBS in the negative group on the microscopic morphology of MRSA. (B) Scanning electron microscope observation shows the effect of PFAP-1 recombinant polypeptide on the microscopic morphology of MRSA.

[0023] Figure 8 The inhibitory effect of PFAP-1 recombinant polypeptide on MRSA biofilm formation and the elimination effect on mature biofilm. Among them, (A) the inhibition of PFAP-1 recombinant polypeptide on MRSA biofilm formation. (B) OD 596 Absorbance numerical statistics results. (C) Elimination effect of PFAP-1 recombinant peptide on MRSA biofilm. (D) OD 596 Statistical results of absorbance values.

[0024] Fig. 9 The hemolytic activity of the PFAP-1 recombinant polypeptide. (A) Hemolysis of 4% rabbit red blood cells by the PFAP-1 recombinant polypeptide at different concentrations. (B) Hemolysis rate statistics of the PFAP-1 recombinant polypeptide at different concentrations.

[0025] Fig.10 The PFAP-1 recombinant polypeptide has the activity of scavenging DPPH free radicals and inhibiting the activity of angiotensin converting enzyme 2. Among them, (A) the PFAP-1 recombinant polypeptide has the activity of scavenging DPPH free radicals (IC 50 =40.83 μg / mL). (B) PFAP-1 recombinant polypeptide inhibits angiotensin converting enzyme 2 activity (IC 50 =5.66 μg / mL). DETAILED DESCRIPTION

[0026] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0027] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0028] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0029] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.

[0030] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0031] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.

[0032] The embodiment of the present invention provides a DNA molecule encoding the active peptide PFAP-1 from Pinctada fucata, and the nucleotide sequence thereof is shown as SEQ ID NO.3.

[0033] The embodiment of the present invention also provides an expression vector, comprising the DNA molecule.

[0034] In some specific embodiments, the expression vector is pET-30a-PFAP-1.

[0035] The embodiment of the present invention also provides an engineered bacterium, comprising the expression vector.

[0036] In some specific embodiments, the engineered bacteria is Escherichia coli containing pET-30a-PFAP-1.

[0037] The embodiment of the present invention also provides a method for preparing the active polypeptide PFAP-1 of the Pearl oyster, using the expression vector to transfect prokaryotic cells to express the active polypeptide PFAP-1 of the Pearl oyster; or using the engineered bacteria to express the active polypeptide PFAP-1 of the Pearl oyster.

[0038] In some specific embodiments, the preparation method comprises the following steps: picking a single colony of Escherichia coli containing pET-30a-PFAP-1, inoculating it into LB liquid culture medium containing 50 μg / mL kanamycin sulfate, and shaking culturing at 37°C until OD 600 The pH value was 0.6-0.8. IPTG was added at a final concentration of 0.2 mM, and the expression was induced at 15°C and 37°C for 16 h, respectively, and the bacteria were collected. After ultrasonic disruption (300 W, ultrasonic for 5 seconds, 5 seconds intermittent, ultrasonic for 30 minutes), the supernatant and precipitate were collected, and the precipitate was washed 3 times with washing solution (50 mMTris (pH8.0), 300 mM NaCl containing 1% Triton X-114, 1% Triton X-100, 2 mM EDTA, 5 mM DTT), and then the inclusion bodies were dissolved with inclusion body dissolution solution (50 mM Tris (pH8.0), 300 mM NaCl, 8 M Urea, 20 mM Imidazole) at 4°C overnight, and loaded onto the Ni-IDA gravity affinity chromatography column pre-equilibrated with the inclusion body dissolution solution, and the target protein was eluted with the equilibrium buffer containing different concentrations of imidazole. Each elution fraction was collected for SDS-PAGE analysis. The eluted fractions with relatively high purity were collected, added to a dialysis bag, and dialyzed into a buffer solution (1×PBS (pH 7.4), 4 mM GSH, 0.4 mM GSSG, 0.4 M L-Arginine, 1 M Urea) at 4°C for renaturation. The renatured protein was finally dialyzed into a storage solution 1×PBS (pH 7.4), and endotoxins were removed using PMB affinity media. Finally, the collected protein was sterilized by filtering with a 0.22 μm filter.

[0039] The embodiment of the present invention also provides the use of the active polypeptide PFAP-1 of the Pearl oyster in the preparation of a product for inhibiting methicillin-resistant Staphylococcus aureus. The amino acid sequence of the active polypeptide PFAP-1 of the Pearl oyster is shown in SEQ ID NO.1.

[0040] The active peptide PFAP-1 from the Hepu pearl oyster is composed of 83 amino acids, with a molecular weight of approximately 10kDa and an isoelectric point of 10.40.

[0041] The embodiment of the present invention also provides the use of the active polypeptide PFAP-1 of the Pinctada fucata in the preparation of antioxidant products. The amino acid sequence of the active polypeptide PFAP-1 of the Pinctada fucata is shown in SEQ ID NO.1.

[0042] The embodiment of the present invention also provides the use of the active polypeptide PFAP-1 of the Pinctada fucata in the preparation of a drug for inhibiting the activity of angiotensin converting enzyme 2. The amino acid sequence of the active polypeptide PFAP-1 of the Pinctada fucata is shown in SEQ ID NO.1.

[0043] Prokaryotically expressed PFAP-1 has significant antibacterial activity against methicillin-resistant staphylococcus aureus (MRSA), low hemolytic activity, strong antioxidant activity and inhibition of angiotensin converting enzyme 2 activity, and has broad application prospects.

[0044] The present invention uses the statistical software IBM SPSS Statistics 19.0 for data analysis, and uses GraphPad Prism 8 software for statistical mapping. All experiments were repeated 3 times, and the quantitative results were expressed as mean ± standard deviation (X ± S). The quantitative numerical comparison between the two groups was performed by independent sample t test, and the quantitative numerical comparison between multiple groups was performed by one-way analysis of variance. In all tests, P < 0.05 was considered to be significantly different and statistically significant, indicated by "*", and P < 0.0001 was considered to be extremely significantly different and statistically significant, indicated by "****".

[0045] Example 1 Codon optimization of the PFAP-1 gene of the active peptide of the pearl oyster and construction of the prokaryotic expression plasmid

[0046] According to the UniProt Pinctada fucata protein database (Taxon ID: 50426), a protein with unidentified function (UniProt protein number: A0A194ALV1) was screened out, and its amino acid sequence is shown in SEQ ID NO.1.

[0047] SEQ ID NO. 1: MENIHSFYPRNLRRHNPILLMNLVHRRRLLGLLIFRALYRLEEEI LLLPRSCRSRFPCRCDCPRLLDSLRSNCKSSSSKLLFDL.

[0048] The complete open reading frame of the gene was obtained, with a total length of 252 bp (GenBank No.: GELH01000748.1), and its nucleotide sequence is shown in SEQ ID NO.2.

[0049] SEQ ID NO.2: 5'-ATGGAAAATATACACAGTTTTTATCCACGGAATCTTCGGCG GCACAATCCCATTCTTCTCATGAATCTAGTACATCGGCGTCGACTACTTGGTCTTCTCATATTTCGAGCGTTGTACCGTCTTGAAGAAGAGATTCTGTTGCTTCCTAGATCGTGTAGATCAAGATTTCCATGCCGCTGTGACTGTCCTCGTCTTCTTGATTCTCTTAGAAGTAACTGCAAATCTTCATCTAAACTTCTTTTTGACTTGTAA-3'.

[0050] Using GenSmart TM Codon optimization (Version Beta 1.0) online software (https: / / www.genscript.com.cn / tools / gensmart%2dcodon%2doptimization?page=1) was used to perform codon optimization on the E. coli expression host, and the codon adaptation index (CAI) and GC content were analyzed using the JAVA codon Adaptation Tool (https: / / www.jcat.de / Start.jsp). The optimized gene was named PFAP-1, and the optimized nucleotide sequence is shown in SEQ ID NO.3.

[0051] SEQ ID NO.3: 5'-ATGGAAAACATCCACAGCTTCTACCCGCGTAACTTACGTC GTCATAACCCGATCCTGCTGATGAATCTGGTTCATCGTCGCCGTTTACTGGGTTTACTGATCTTTCGCGCGCTGTATCGTCTGGAAGAAGAAATCCTGCTGTTACCGCGTAGCTGTCGTTCTCGTTTTCCGTGTCGTTGCGATTGTCCGCGTTTACTGGATTCTCTGCGTAGTAACTGCAAATCCAGCAGCAAACTGCTGTTCGATCTGTAA-3'.

[0052] A DNA sequence containing Nde I and HindIII restriction endonuclease sites was synthesized by chemical methods. Subsequently, it was connected to the pET-30a vector. After double enzyme digestion and sequencing verification, the recombinant plasmid was transferred into Escherichia coli BL21 (DE3) competent cells to construct an Escherichia coli engineered strain capable of expressing the Hepu Pearl Oyster PFAP-1.

[0053] Example 2 Bioinformatics analysis of the active peptide PFAP-1 of Pinctada fucata

[0054] ProtParam (https: / / web.expasy.org / protparam / ) was used to predict the physicochemical properties of the PFAP-1 polypeptide. DeepTMHMM (https: / / dtu.biolib.com / DeepTMHMM) was used to predict the transmembrane structure of the PFAP-1 polypeptide. SOPM (https: / / npsa-pbil.ibcp.fr / cgi-bin / npsa_automat.pl?page=npsa_sopma.html) was used to predict the secondary structure. The complete three-dimensional structure of the PFAP-1 polypeptide was predicted using I-TASSER (https: / / zhanggroup.org / I-TASSER / ) software and visualized using PyMOL software.

[0055] The results are shown in Table 1. Figure 2 As shown, PFAP-1 protein consists of 83 amino acid residues, with a molecular weight of approximately 10.00 kDa, an estimated isoelectric point of 10.40, a total net charge of +9, and a hydrophobicity of 43% (Table 1). DeepTMHMM prediction results show that PFAP-1 protein does not contain a signal peptide and is an intracellular protein ( Figure 2 The SOPMA prediction results showed that the secondary structure of PFAP-1 protein was mainly composed of α-helix (43.37%), random coil (34.94%), extended chain (18.07%) and β-turn (3.61%) ( Figure 2 The tertiary structure of the full-length PFAP-1 protein was predicted using I-TASSER software and displayed using PyMol software. It is mainly composed of three α-helices, located at Glu2-Arg27, Leu29-Ser54, C62-Asp82 ( Figure 2 Middle C).

[0056] Table 1 Physicochemical properties of PFAP-1 protein

[0057]

[0058] Example 3 Prokaryotic expression, preparation and identification of the active polypeptide PFAP-1 from the pearl oyster

[0059] A single colony of E. coli containing pET-30a-PFAP-1 was picked and inoculated into LB liquid medium containing 50 μg / mL kanamycin sulfate, and cultured at 37°C with shaking until OD 600 The pH value was 0.6-0.8. IPTG was added at a final concentration of 0.2 mM, and the expression was induced at 15°C and 37°C for 16 h, and the bacteria were collected. After ultrasonic disruption (300 W, ultrasonic for 5 seconds, 5 seconds intermittent, ultrasonic for 30 minutes), the supernatant and precipitate were collected, and the precipitate was washed 3 times with washing solution (50 mM Tris (pH 8.0), 300 mM NaCl containing 1% Triton X-114, 1% Triton X-100, 2 mM EDTA, 5 mM DTT), and then the inclusion bodies were dissolved with inclusion body dissolution solution (50 mM Tris (pH 8.0), 300 mM NaCl, 8 M Urea, 20 mM Imidazole) at 4°C overnight, and loaded onto the Ni-IDA gravity affinity chromatography column pre-equilibrated with the inclusion body dissolution solution, and the target protein was eluted with the equilibrium buffer containing different concentrations of imidazole. Each elution fraction was collected for SDS-PAGE analysis. The eluted fractions with relatively high purity were collected, added to the dialysis bag, dialyzed into the buffer (1×PBS (pH7.4), 4mM GSH, 0.4mM GSSG, 0.4M L-Arginine, 1M Urea) at 4°C for renaturation, and the renatured protein was finally dialyzed into the storage solution 1×PBS (pH 7.4), and the endotoxin was removed using PMB affinity medium. Finally, the collected protein was sterilized by filtration with a 0.22μm filter, the protein concentration was measured by the BCA protein concentration assay kit, aliquoted, and frozen at -80°C. The expression of the recombinant polypeptide PFAP-1 was verified by Western blot using HA-tagged mouse monoclonal antibody as the primary antibody and horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) as the secondary antibody.

[0060] The results are as follows Figures 3-4 As shown, the verified recombinant expression plasmid was transferred into Escherichia coli BL21 (DE3), and IPTG was used to induce expression. The bacteria were collected for SDS-PAGE analysis. Compared with the uninduced group, PFAP-1 was significantly expressed under the induction conditions of 15°C and 37°C. After the bacteria were ultrasonically disrupted, SDS-PAGE was used to analyze its expression form. The results showed that the supernatant and precipitate after disruption had the target protein distribution ( Figure 3 However, due to too many impurities in the supernatant, the target protein was not purified from it ( Figure 3 We decided to purify the target protein from the inclusion body, and the results showed that there was an obvious recombinant protein expression band at the 15kDa band ( Figure 3C), collect the eluted fractions with higher purity, perform renaturation, dialysis, endotoxin removal and filtration sterilization, and finally obtain a protein concentration of 0.60 mg / mL. Take 0.6 μg for SDS-PAGE detection, and the results show that there is a specific band at 15 kDa, with high purity ( Figure 3 D), WB verification results showed that there was still a specific band at the same molecular weight position ( Figure 3 E), indicating that the low-endotoxin, sterile, and high-purity PFAP-1 recombinant protein was successfully prepared. The molecular weight of the PFAP-1 recombinant protein was determined by MALDI-TOF-TOF, and the results showed that its molecular weight was approximately 11.10 kDa, which was basically consistent with the expectation ( Figure 4 A), the amino acid sequence of the PFAP-1 recombinant protease cleaved peptide was identified by LC-MS. The results showed that the detected fragment ion peaks were highly matched with the theoretical fragment peaks. The secondary fragment ion peaks of the protein-specific peptide CDCPRLLDSLRSNCK were as follows Figure 4 As shown in B, it indicates that the purified protein is PFAP-1 recombinant protein.

[0061] Example 4 Detection of antibacterial activity of recombinant Pinctada fucata active peptide PFAP-1 by Oxford cup method

[0062] 1) Preparation of bacterial suspension: Scrape the methicillin-resistant Staphylococcus aureus (ATCC43300) bacterial lawn from the test tube slope, inoculate into 4 mL LB medium, and culture at 37°C, 180 rpm, shaking overnight. Then dilute the bacterial suspension 6 times and measure the OD 600 , so that the range is between 0.3 and 0.8, and then multiply the OD by the dilution factor 600 The value is the OD of the original bacterial solution. 600 , dilute to 1×10 using LB ten-fold dilution method 6 CFU / mL bacterial suspension for later use (1OD 600 About 1×10 9 CFU / mL).

[0063] 2) The double-layer plate transparent circle method was used, that is, 10 mL of autoclaved agar (1.5%) (lower layer) was poured into a 90 mm sterile culture dish. After solidification, 4 sterilized Oxford cups were quickly placed on the plate. The inner diameter of the Oxford cup was (6±0.1) mm, the outer diameter was (7.8±0.1) mm, and the height was (10±0.1) mm. 15 mL of the culture medium mixed with the test bacteria was added under sterile conditions. After the culture medium solidified, the Oxford cup was taken out, and 100 μL of negative control PBS and the prepared recombinant peptide PFAP-1 (0.6 mg / mL) were added to each well. The plate was pre-diffused at 4°C for 2-4 hours, and then cultured in a 37°C incubator for 16-20 hours. The diameter of the inhibition zone was observed and measured. Each inhibition zone was measured 3 times, and 3 independent repeated experiments were performed to take the average value.

[0064] The results are as follows Figure 5 As shown, the PFAP-1 recombinant protein had an obvious inhibition zone against MRSA, with a diameter of 15.99±0.02mm.

[0065] Example 5 96-well method for measuring the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of PFAP-1

[0066] 1) Prepare bacterial suspension as in Example 4;

[0067] 2) Take a sterile 96-well plate, add 100 μL of sterile LB medium + 100 μL PBS to well 1 of each row as a blank control, and add 100 μL of freshly prepared 10 6 CFU / mL test bacterial suspension, 100 μL of PFL-96 polypeptide at 300, 150, 75, 37.5, 18.75, 9.38, 4.69, 2.34, 1.17 and 0.59 μg / mL was added to wells 3-12, and the final drug concentrations in each well were 150, 75, 37.5, 18.75, 9.38, 4.69, 2.34, 1.17, 0.59 and 0.30 μg / mL, respectively, and 100 μL of PBS was added to well 2 as a negative control. Three replicates were added to each group.

[0068] 3) The 96-well plate was placed in a 37°C incubator for 18 h, 1 μL of 1% 2,3,5-triphenyl tetrazolium chloride (TTC) was added to each well, the minimum dilution at which no red change was observed by the naked eye was taken as the MIC, and the OD was measured by an enzyme-labeled instrument. 485 The absorbance was measured, and 20 μL of culture was taken from the wells where no red change was observed by the naked eye to spread on the plate. The plate was cultured at an appropriate temperature for 24 h, and the growth of colonies in the plate was observed. The minimum concentration of the drug corresponding to no growth of colonies or less than 5 growth colonies was taken as MBC. All experiments were repeated 3 times independently.

[0069] The results are as follows Figure 6 As shown, the MIC of PFAP-1 recombinant protein against MRSA was 37.5 μg / mL ( Figure 6 The results of the plate coating method showed that MBC was 150 μg / mL ( Figure 6 Middle C).

[0070] Example 6 Effect of recombinant Pinctada pueraria active polypeptide PFAP-1 on MRSA growth curve

[0071] Take a sterile 96-well plate, add 100 μL sterile broth medium and 100 μL PBS to the first column as a blank control, and add 100 μL PFAP-1 and 100 μL 10 to columns 3-7, respectively. 8 CFU / mL bacterial suspension (preparation method as in Example 4), so that the final concentration of PFAP-1 is 37.5, 75 and 150 μg / mL, respectively, 100 μL of sterile PBS and 100 μL of bacterial suspension are added to the second column as a negative control, and 3 replicates are set for each group; 2) Place in an ELISA instrument, measure once every 2 hours, measure continuously for 24 hours, and draw a growth curve.

[0072] The results are as follows Figure 6 As shown in D, compared with the negative control group, all PFAP-1 recombinant proteins were able to significantly inhibit the growth of MRSA, especially at 1 and 2×MIC concentrations, the MRSA growth level was extremely low.

[0073] Example 7 Scanning electron microscope observation of MRSA microscopic morphological changes

[0074] 1) Preparation 10 8 CFU / mL bacterial suspension (method as in Example 4);

[0075] 2) Add PFAP-1 active polypeptide to a final concentration of 37.5 μg / mL, and set PBS as a negative control;

[0076] 3) Incubate at 37°C with shaking at 100 rpm for 4 h, centrifuge at 4000 rpm for 5 min, discard the supernatant, wash with sterile saline three times, and collect the cells by centrifugation at 4000 rpm for 10 min;

[0077] 4) Fix with 1 mL 2.5% glutaraldehyde at 4°C overnight;

[0078] 5) Scanning electron microscopy observation was performed.

[0079] The results are as follows Figure 7 As shown, the MRSA in the negative group has a clear, smooth and complete morphology, with a typical spherical structure ( Figure 7In the 1×PFAP-1 treatment group, MRSA showed obvious cracks and grooves, and the surface became rougher ( Figure 7 Middle B), indicating that PFAP-1 recombinant protein had a certain destructive effect on MRSA cell wall and cell membrane.

[0080] Example 8 Detection of inhibition and elimination of MRSA biofilm by recombinant Pinctada fucata active peptide PFAP-1

[0081] MRSA cells were suspended in LB medium (LB-G) containing glucose at a final concentration of 0.5% and diluted to 1×10 8 The final concentrations of PFAP-1 were set to 1 / 4, 1 / 2 and 1×MIC (9.375, 18.75 and 37.5 μg / mL), the LB-G medium without bacteria was used as the blank control, and the PBS containing bacteria but without PFAP-1 was used as the negative control. Take 100 μL of bacterial suspension, add 100 μL of different concentrations of PFAP-1 and PBS, place in a 96-well plate, set up 3 replicates, incubate in a constant temperature incubator at 37°C for 48 hours, discard the suspension, rinse three times with PBS, fix with anhydrous methanol for 15 minutes, air-dry at room temperature, stain with 0.1% crystal violet at room temperature for 15 minutes, aspirate the crystal violet, wash with sterile water until clear, invert on filter paper to remove excess water, dry at 37°C, take pictures to observe the biofilm attachment, add 33% glacial acetic acid, incubate at 37°C for 30 minutes to fully dissolve the attached crystal violet, measure the absorbance at 595 nm with an enzyme marker, and evaluate the inhibitory effect of PFAP-1 on MRSA biofilm formation.

[0082] MRSA cells were suspended in LB medium (LB-G) containing glucose at a final concentration of 0.5% and diluted to 1×10 8 CFU / mL, 200 μL was added to a 96-well plate, the blank group was a sterile LB-G medium, three replicate wells were set, and the biofilm was preformed in a 37°C constant temperature incubator for 48 hours. The suspension was discarded, and the wells were gently rinsed 3 times with PBS. 200 μL of different concentrations of PFAP-1 were added to the experimental group, and 200 μL of PBS was added to the blank group and the negative group, and the biofilm was preformed in a 37°C constant temperature incubator for 24 hours. Subsequent operations were the same as the biofilm inhibition experiment to evaluate the elimination effect of PFAP-1 on MRSA mature biofilm.

[0083] The results are as follows Figure 8 As shown in the figure, the negative group MRSA can obviously form biofilm, and the recombinant protein PFAP-1 treatment group can significantly inhibit the formation of MRSA biofilm ( Figure 8 A and B). For the elimination experiment of mature biofilm, the results showed that compared with the negative group, the recombinant protein PFAP-1 had a significant elimination effect on MRSA mature biofilm ( Figure 8 (C, D).

[0084] Example 9 Detection of hemolytic activity of recombinant Pinctada pueraria active peptide PFAP-1

[0085] 1) 4% rabbit red blood cells were used for hemolytic activity detection. PFAP-1 was diluted to 600, 300, 150, 75, 37.5, 18.75, 9.38, 4.69, 2.34 and 1.17 μg / mL with PBS according to the doubling dilution method, and 100 μL of PFAP-1 was added to a 96-well plate as the experimental group. 100 μL of PBS and 1.0% Triton X-100 were taken as negative control and positive control, respectively. 100 μL of 4% red blood cell suspension was added to each well, and 3 replicates were made for each group, so that the final concentrations of PFAP-1 were: 300, 150, 75, 37.5, 18.75, 9.38, 4.69, 2.34, 1.17 and 0.59 μg / mL;

[0086] 2) Incubate at 37°C for 3 h, centrifuge at 1500 rpm for 10 min, take 150 μL of supernatant and transfer to a new 96-well plate, measure the absorbance at 450 nm, and calculate the hemolysis rate.

[0087] Hemolysis rate = [OD 450 - Negative control group OD 450 ] / [OD of positive control group 450 - Negative control group OD 450 ]×100%.

[0088] The results are as follows Fig. 9 As shown, when the final concentration of PFAP-1 recombinant protein is 300 μg / mL, it has a high hemolysis rate (96.78%), and when it is 150 μg / mL, its hemolysis rate is low, which is 11.21%. When the final concentration of PFAP-1 recombinant protein is 75 μg / ml and below, its hemolytic activity can be ignored. This shows that within its effective antibacterial concentration range, PFAP-1 recombinant protein has low hemolytic activity against mammalian blood cells.

[0089] Example 10 Detection of the antioxidant activity and inhibition of angiotensin converting enzyme 2 activity of the recombinant Pinctada pueraria active peptide PFAP-1

[0090] The DPPH free radical scavenging ability kit (Cat. No. A153-1-1) of Nanjing Jiancheng Bioengineering Institute was used to detect the antioxidant activity of the recombinant Pinctada pumarica active peptide PFAP-1. The blank tube was 400 μL 80% methanol plus 600 μL of the working solution in the kit, the control tube was 400 μL sample plus 600 μL 80% methanol, and the test tube was 400 μL of PFAP-1 with different concentrations plus 600 μL of working solution, so that the final concentration of PFAP-1 was 180, 90, 45, 22.5, 11.25, 5.625 and 0 μg / mL. Three parallel tubes were set up, mixed and placed at room temperature in the dark for 30 minutes, centrifuged at 4000 rpm for 5 minutes, 800 μL was drawn into the cuvette, zeroed with anhydrous ethanol, and the OD of each tube was measured. 517 Absorbance. DPPH free radical scavenging rate (%) was calculated using the formula: (1-(A 测定 -A 对照 )÷A 空白 )×100%.

[0091] The angiotensin-converting enzyme 2 (ACE2) inhibitor screening kit (product number: P0320S) of Shanghai Biyuntian Biotechnology Co., Ltd. was used to detect the inhibitory activity of the recombinant Pinctada pueraria active peptide PFAP-1 on ACE2. A blank control, a 100% enzyme activity control, a test group, and a positive control were set. The final concentration of PFAP-1 peptide in the test group was 16, 8, 4, 2, 1, 0.5, and 0.25 μg / mL. After adding all reagents according to the instructions, the black transparent 96-well plate was placed at 37°C in the dark for 30 minutes, and then the fluorescence of each group was measured using a multifunctional enzyme label. The excitation wavelength was 325nm and the emission wavelength was 393nm.

[0092] ACE2 inhibition rate (%) = (RFU 100% enzyme activity control - RFU sample) / (RFU 100% enzyme activity control - RFU blank control) × 100%.

[0093] The results are as follows Fig.10 As shown in Figure 2, compared with vitamin C, the recombinant protein PFAP-1 has a weaker ability to scavenge DPPH. At its highest concentration, the scavenging rate of DPPH is 79.67%. Its IC 50 40.83 μg / mL ( Fig.10 A). The inhibitory activity of the recombinant protein PFAP-1 on ACE2 was low in the range of 0.5-4 μg / mL. When its concentration was greater than 4 μg / mL, the inhibition rate on ACE2 increased significantly, and basically reached its maximum inhibition rate at 8-16 μg / mL. Its IC 50 5.66 μg / mL ( Fig.10 (middle B).

[0094] Obviously, the above embodiments of the present invention are merely examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A DNA molecule encoding the active peptide PFAP-1 from the pearl oyster, characterized in that: Its nucleotide sequence is shown in SEQ ID NO.

3.

2. An expression vector, characterized in that: Comprising the DNA molecule according to claim 1.

3. The expression vector according to claim 2, characterized in that The expression vector is pET-30a-PFAP-1.

4. An engineered bacterium, characterized in that: Comprising the expression vector according to claim 2 or 3.

5. A method for preparing the active polypeptide PFAP-1 from Pinctada fucata, characterized in that: The expression vector according to claim 2 or 3 is used to transfect prokaryotic cells to express the Pinctada fucata active polypeptide PFAP-1; or the engineered bacteria according to claim 4 are used to express the Pinctada fucata active polypeptide PFAP-1.

6. Use of the active polypeptide PFAP-1 from the pearl oyster of Hepu in the preparation of a product for inhibiting methicillin-resistant Staphylococcus aureus, characterized in that: The amino acid sequence of the Pinctada fucata active polypeptide PFAP-1 is shown in SEQ ID NO.

1.

7. Application of the active polypeptide PFAP-1 from the pearl oyster of Hepu in the preparation of antioxidant products, characterized in that: The amino acid sequence of the Pinctada fucata active polypeptide PFAP-1 is shown in SEQ ID NO.

1.

8. Use of the active polypeptide PFAP-1 from the pearl oyster of Hepu in the preparation of a drug for inhibiting the activity of angiotensin converting enzyme 2, characterized in that: The amino acid sequence of the Pinctada fucata active polypeptide PFAP-1 is shown in SEQ ID NO.1.